Investigational drugs for the treatment of diffuse large B-cell lymphoma
Andrea Patriarca, Gianluca Gaïdano
Abstract
: A precision medicine strategy based on robust molecular predictors of outcome is desirable in the development of investigational small molecules for DLBCL. Novel monoclonal and bispecific antibodies may be offered to (i) relapsed/refractory patients ineligible for CAR-T cells because of comorbidities, and (ii) younger patients before CAR-T cell infusion to reduce a high tumor burden. A focus on the optimal sequencing of the emerging DLBCL drugs is appropriate and necessary.
Topics & Concepts
MedicineDiffuse large B-cell lymphomaDruggabilityLymphomaOncologyClinical trialMonoclonal antibodyBrentuximab vedotinRituximabCancer researchInternal medicineImmunologyAntibodyBiologyCD30GeneBiochemistryCAR-T cell therapy researchLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research